Meta-analysis: Diagnostic Value of Serum Anti-mutated Citrullinated Vimentin Antibodies in Patients with Rheumatoid Arthritis

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 2010 Mar 12

PMID 20221607

Citations 9

Authors

Xue Qin

Yan Deng

Jing Xu

Tai-Jie Li

Shan Li

Jin-Min Zhao

Affiliations

Soon will be listed here.

Abstract

Conventional tests are not always helpful in making a diagnosis of rheumatoid arthritis (RA). This study aimed to comprehensively and quantitatively summarize the evidence on the accuracy of anti-mutated citrullinated vimentin (MCV) assay in the diagnosis of RA. A comprehensive meta-review of data on the accuracy of MCV concentrations in the diagnosis of RA were carried out from 16 published studies. Furthermore, receiver operating characteristic curves were used to summarize the overall test performance. The summary estimates for MCV in the diagnosis of RA were: sensitivity 0.77 [95% confidence interval (CI) 0.75-0.78], specificity 0.89 (95% CI 0.87-0.90), positive likelihood ratio (LR+) 7.24 (95% CI 5.60-9.36), negative likelihood ratio (LR-) 0.28 (95% CI 0.23-0.34) and diagnostic odds ratio 29.66 (95% CI 21.09-41.71). The area under the summary receiver operating characteristic curves was 0.92. Data from meta-analysis suggest the accuracy of MCV assay in the diagnosis of RA is high, but ultimately clinician must consider the results of MCV tests combing with other conventional examinations and the clinical feature.

Citing Articles

Evaluation of autoantibodies against vimentin and α-enolase in rheumatoid arthritis patients.

Ebrahimi-Rad M, Khatami S, Akhbari H, Mahmoudzadeh-Niknam H, Valadbeigi S, Mahmoudi M Reumatologia. 2021; 58(6):350-356.

PMID: 33456077 PMC: 7792540. DOI: 10.5114/reum.2020.101276.

Meta-Analysis: Diagnostic Accuracy of Anti-Carbamylated Protein Antibody for Rheumatoid Arthritis.

Li L, Deng C, Chen S, Zhang S, Wu Z, Hu C PLoS One. 2016; 11(7):e0159000.

PMID: 27437936 PMC: 4954701. DOI: 10.1371/journal.pone.0159000.

Diagnostic performance of a new vimentin-derived ACPA (CCP high sensitive) in patients with rheumatoid arthritis.

Bertin D, Dubucquoi S, Lakomy D, Deleplancque A, Desplat-Jego S Immunol Res. 2015; 64(2):455-60.

PMID: 26350265 DOI: 10.1007/s12026-015-8690-9.

Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis.

Lindenberg L, Spengler L, Bang H, Dorner T, Maslyanskiy A, Lapin S Arthritis Res Ther. 2015; 17:206.

PMID: 26268352 PMC: 4535682. DOI: 10.1186/s13075-015-0717-z.

Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab.

Fabris M, De Vita S, Blasone N, Visentini D, Pezzarini E, Pontarini E Auto Immun Highlights. 2015; 1(2):87-94.

PMID: 26000112 PMC: 4389048. DOI: 10.1007/s13317-010-0013-5.

References

Schellekens G, de Jong B, van den Hoogen F, van de Putte L, van Venrooij W . Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998; 101(1):273-81. PMC: 508564. DOI: 10.1172/JCI1316. View

Mutlu N, Bicakcigil M, Tasan D, Kaya A, Yavuz S, Ozden A . Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis. J Rheumatol. 2009; 36(3):491-500. DOI: 10.3899/jrheum.080656. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Bang H, Egerer K, Gauliard A, Luthke K, Rudolph P, Fredenhagen G . Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 2007; 56(8):2503-11. DOI: 10.1002/art.22817. View

Petitti D . Approaches to heterogeneity in meta-analysis. Stat Med. 2001; 20(23):3625-33. DOI: 10.1002/sim.1091. View

Soos L, Szekanecz Z, Szabo Z, Fekete A, Zeher M, Horvath I . Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol. 2007; 34(8):1658-63. View

Glas A, Lijmer J, Prins M, Bonsel G, Bossuyt P . The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003; 56(11):1129-35. DOI: 10.1016/s0895-4356(03)00177-x. View

MOSES L, Shapiro D, Littenberg B . Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993; 12(14):1293-316. DOI: 10.1002/sim.4780121403. View

Schellekens G, Visser H, de Jong B, van den Hoogen F, Hazes J, Breedveld F . The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000; 43(1):155-63. DOI: 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3. View

10.

Poulsom H, Charles P . Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clin Rev Allergy Immunol. 2008; 34(1):4-10. DOI: 10.1007/s12016-007-8016-3. View

11.

Takasaki Y, Yamanaka K, Takasaki C, Matsushita M, Yamada H, Nawata M . Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol. 2006; 14(5):367-75. DOI: 10.1007/s10165-004-0325-2. View

12.

Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U . Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol. 1995; 22(12):2208-13. View

13.

Duval S, Tweedie R . Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-63. DOI: 10.1111/j.0006-341x.2000.00455.x. View

14.

Coenen D, Verschueren P, Westhovens R, Bossuyt X . Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem. 2007; 53(3):498-504. DOI: 10.1373/clinchem.2006.078063. View

15.

El-Gabalawy H, Wilkins J . Anti-Sa antibodies: prognostic and pathogenetic significance to rheumatoid arthritis. Arthritis Res Ther. 2004; 6(2):86-9. PMC: 400444. DOI: 10.1186/ar1171. View

16.

Mathsson L, Mullazehi M, Wick M, Sjoberg O, van Vollenhoven R, Klareskog L . Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2008; 58(1):36-45. DOI: 10.1002/art.23188. View

17.

Despres N, Boire G, Lopez-Longo F, Menard H . The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol. 1994; 21(6):1027-33. View

18.

Quinn M, Emery P . Potential for altering rheumatoid arthritis outcome. Rheum Dis Clin North Am. 2005; 31(4):763-72. DOI: 10.1016/j.rdc.2005.07.008. View

19.

Vossenaar E, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T . Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther. 2004; 6(2):R142-50. PMC: 400433. DOI: 10.1186/ar1149. View

20.

Deville W, Buntinx F, Bouter L, Montori V, de Vet H, van der Windt D . Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002; 2:9. PMC: 117243. DOI: 10.1186/1471-2288-2-9. View